Dipyridamole for coronary artery bypass surgery

Area of Science:

• Cardiology
• Pharmacology
• Transfusion Medicine

Background:

• Coronary artery bypass graft (CABG) surgery carries risks of bleeding and myocardial injury.
• Platelet activation and deposition are implicated in perioperative cardiac complications.
• Dipyridamole is a medication with antiplatelet and vasodilatory properties.

Purpose of the Study:

• To compare the efficacy of oral versus intravenous dipyridamole in CABG patients.
• To evaluate dipyridamole's effects on platelet and leukocyte deposition in the myocardium.
• To assess dipyridamole's impact on cardiac thromboxane release and postoperative bleeding.

Main Methods:

• Two randomized trials involving patients undergoing CABG surgery.
• Administration of oral or intravenous dipyridamole versus placebo.
• Measurement of plasma drug concentrations, platelet counts, and blood loss.
• Use of radiolabeled platelets and leukocytes (111In, 99mTc) to assess myocardial deposition.
• Measurement of cardiac thromboxane B2 release.

Main Results:

• Both oral and intravenous dipyridamole significantly reduced postoperative blood loss and transfusion requirements.
• Intravenous dipyridamole led to higher postoperative platelet counts compared to oral administration and controls.
• Dipyridamole administration reduced myocardial deposition of platelets and leukocytes during reperfusion.
• Cardiac release of thromboxane B2 was decreased by dipyridamole.

Conclusions:

• Dipyridamole effectively preserves platelets and reduces bleeding and blood product transfusions in CABG patients.
• Perioperative dipyridamole mitigates myocardial platelet and leukocyte deposition.
• Dipyridamole may lessen perioperative ischemic injury by reducing thromboxane release.